Myocardial Contractile Function in Patients with Liver Cirrhosis and Syndrome of Bacterial Overgrowth Syndrome

Objective: to study myocardial contractile function in patients with liver cirrhosis and ascites in the presence of bacterial overgrowth syndrome (BOS) and pathological bacterial translocation. Materials and methods. We included in this study 59 patients with Child-Pugh class B and C liver cirrhosis (LC) of various etiology and ascites. Control group comprised 12 patients with ischemic heart disease complicated by chronic heart failure (CHF). Examination included history taking and laboratory and instrumental investigation. LC was diagnosed basing on clinical symptoms and instrumental studies. Child-Pugh and MELD scores were used for assessment of LC severity and prognosis. International ascites club grading system was used for evaluation of severity of ascites. Hydrogen breath test was applied for diagnosing BOS. Syndrome of pathological bacterial translocation was established based on blood levels of lipopolysaccharide-binding protein and detection of bacterial DNA in ascitic fluid. Structural-functional parameters of the myocardium and hemodynamics were assessed by echocardiography. Brain natriuretic peptide (BNP) concentration was measured in blood serum and ascitic fluid. Results. In 13 of 59 patients with LC the hydrogen breath test was negative, in 33 positive and in 13 patients the positive hydrogen test was combined with the presence of BOS and pathological bacterial translocation. Blood serum and ascitic fluid BNP concentrations in LC patients were low and within normal limits (62.5±4.1 and 53.3±4.9 rg / ml, respectively), what contrasted with high BNP concentrations in patients with CHF (1820±95.5 and 497.1±39.6 rg / ml, respectively). Total protein level in ascitic fluid also was significantly lower in patients with LC than in patients with CHF (1.77±0.1 and 4.43±0.35 mg / dL, respectively). The serum-ascitic albumin gradient (SAAG) in both groups of patients exceeded 1.1 (1.58±0.13 in patients with CHF and 1.88±0.19 in patients with LC). Conclusions. In patients with liver cirrhosis the presence of BOS and bacterial translocation did not produce a distinct negative impact on contractile function.

1. Runyon BA. The Serum-Ascites Albumin Gradient Is Superior to the Exudate-Transudate Concept in the Differential Diagnosis of Ascites. Annals of Internal Medicine. 1992;117(3):215. DOI: 10.7326/0003-4819-117-3-215

2. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. The Lancet. 2003;362(9380):316–22. DOI: 10.1016/S0140-6736(03)13976-1

3. Suttner SW, Boldt J. Natriuretic peptide system: physiology and clinical utility: Current Opinion in Critical Care. 2004;10(5):336–41. DOI: 10.1097/01.ccx.0000135513.26376.4f

4. Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JGF et al. State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure. 2008;10(9):824–39. DOI: 10.1016/j.ejheart.2008.07.014

5. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassel BW et al. Cirrhotic Cardiomyopathy. Journal of the American College of Cardiology. 2010;56(7):539–49. DOI: 10.1016/j.jacc.2009.12.075

6. Henriksen JH. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52(10):1511–7. DOI: 10.1136/gut.52.10.1511

7. Yildiz R, Yildirim B, Karincaoglu M, Harputluoglu M, Hilmioglu F. Brain natriuretic peptide and severity of disease in non-alcoholic cirrhotic patients: BNP in cirrhosis. Journal of Gastroenterology and Hepatology. 2005;20(7):1115–20. DOI: 10.1111/j.1440-1746.2005.03906.x

8. Fernández-Esparrach G, Sánchez-Fueyo A, Ginès P, Uriz J, Quintó L, Ventura P-J et al. A prognostic model for predicting survival in cirrhosis with ascites. Journal of Hepatology. 2001;34(1):46–52. DOI: 10.1016/S0168-8278(00)00011-8

9. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine. 1992;20(6):864–74. PMID: 1597042

10. Harrison’s principles of internal medicine. 15 ed. -New York: McGraw-Hill; Braunwald E, Harrison TR. 2001. 91–94pp. ISBN 978-0-07-007272-5

11. Moore KP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(suppl_6):vi1–12. DOI: 10.1136/gut.2006.099580

12. Moore K. The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66. DOI: 10.1053/jhep.2003.50315

13. Rimola A, García-Tsao G, Navasa M, Piddock LJV, Planas R, Bernard B et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Journal of Hepatology. 2000;32(1):142–53. DOI: 10.1016/S0168-8278(00)80201-9

14. Schiller LR. Evaluation of small bowel bacterial overgrowth. Current Gastroenterology Reports. 2007;9(5):373–7. PMID: 17991337

15. Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P et al. Recommendations for chamber quantification. European Journal of Echocardiography. 2006;7(2):79–108. DOI: 10.1016/j.euje.2005.12.014

16. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Journal of the American Society of Echocardiography: Official Publication of the American Society of Echocardiography. 2009;22(2):107–33. DOI: 10.1016/j.echo.2008.11.023

17. Nasledov A.D. IBM SPSS Statistics 20 and AMOS. Professional statistical data analysis. -St. Petersburg: Piter, 2013. -416 p. ISBN 978-5-496-00107-6

18. Rebrova O.Yu. Statistical analysis of medical data. Application software package STATISTICA. -M.: Media Sfera, 2006. -312 p. ISBN 978-5-89084-013-4

19. Mant J. Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. Annals of Internal Medicine. 2011;155(4):252. DOI: 10.7326/0003-4819-155-4-201108160-00009

20. Bari K. Treatment of portal hypertension. World Journal of Gastroenterology. 2012;18(11):1166–75. DOI: 10.3748/wjg.v18.i11.1166

21. Farias AQ, Silvestre OM, Garcia-Tsao G, da Costa Seguro LFB, de Campos Mazo DF, Bacal F et al. Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: A diagnostic accuracy study: Hepatology. Hepatology. 2014;59(3):1043–51. DOI: 10.1002/hep.26643